SOURCE: Active Biotech

November 05, 2009 02:38 ET

Active Biotech AB Interim Report, January - September 2009

LUND, SWEDEN--(Marketwire - November 5, 2009) -


* Laquinimod -- new data presented at ECTRIMS
* 57-57 -- exploratory clinical trial in progress
* RhuDex™ -- clinical development to continue following feedback
  from UK MHRA
* ANYARA -- complete Phase I data published
* TASQ -- complete Phase I data published
* ISI -- project proceeding according to plan
* Net sales of SEK 7.7 M (8.8)
* Operating loss of SEK 164.6 M (loss: 167.0)
* Loss after tax of SEK 165.1 M (loss: 162.0)
* Loss per share for the period amounted to SEK 2.90 (loss: 3.30)
* Number of shares at the end of the period, thousands (incl.
  warrants): 64,943



  For further information, please contact:
  Tomas Leanderson
  President and CEO
  Tel: +46 (0)46-19 20 95

  Göran Forsberg
  VP Investor Relations & Business Development
  Tel: +46 (0)46-19 11 54

  Hans Kolam
  CFO
  Tel: +46 (0)46-19 20 44

  Active Biotech AB
  (Corp. Reg. No. 556223-9227)
  PO Box 724, SE-220 07 Lund
  Sweden
  Tel: +46 (0)46-19 20 00
  Fax: +46 (0)46-19 11 00

  This report is also available at www.activebiotech.com

Active Biotech AB Interim Report, January - September 2009: http://hugin.info/1002/R/1352670/327332.pdf

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.

Contact Information